Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study
Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study have?
Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study published?
Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study has 2024 year in the ScholarIQ index.
What is the open-access status of Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study?
Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study has closed oa status in the ScholarIQ index.
What is the DOI of Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study?
The DOI for Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study is on the source record.
What is the OpenAlex record for Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study?
The OpenAlex for Personalized Tumor Neoantigen Peptide Vaccine Combined with Radiotherapy in the Treatment of Advanced Tumors - Phase II Randomized Group Study is on the source record.